From October 30 to November 2, the 6th Annual Targeted Protein Degradation Summit was held in Boston, USA. Dr. Susan Wang, Senior Vice President of Polymed Biotech, presented HPB-143 preclinical data in a poster format .

 Polymed IRAK4 PROTAC (HPB-143) has demonstrated therapeutic potential in preclinical studies, with excellent protein degradation effect and kinase selectivity, good oral administration pharmacokinetics，dose-dependent efficacy and controllable safety in animal models.

Dr. Susan Wang shared the latest research progress in the field of protein degradation technology and explored the future development direction of protein degradation drugs with global colleagues.